INTERCEPT will address the early detection of breast cancer by developing and validating a liquid biopsy-based companion to mammography with a focus on the ‘intent to treat’ population of patients to gain sufficient evidence for clinical implementation. The proposed work will explore machine learning techniques to improve the identification of rare events in the context of breast cancer screening.
